G. Dusheiko

Hepatology · 2009–2020

A researcher in the Science corpus: 9 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom G. Dusheiko trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Lavanchy

Papers from G. Dusheiko's perspective

Ordered by how strongly the researchers G. Dusheiko trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Sofosbuvir for previously untreated chronic hepatitis C infection. (New England Journal of Medicine)
  2. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. (New England Journal of Medicine)
  3. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. (New England Journal of Medicine)
  4. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. (New England Journal of Medicine)
  5. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive… (The Lancet)
  6. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination… (The Lancet)
  7. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. (Journal of Clinical Epidemiology)
  8. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. (Gastroenterology)
  9. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
  10. Sampling variability of liver fibrosis in chronic hepatitis C (Hepatology)

Their papers